Department of Health
and Human Services (HHS)
and Human Services (HHS)
November 12, 2020
PA-19-050 - Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in PA-19-050: "Engaging Men in HIV Testing, Prevention, and Care (R21 Clinical Trial Optional)."
The following text has been added to reflect NIDA's participation in this FOA:
Part 1. Overview Information
Components of Participating Organizations
National Institute on Drug Abuse (NIDA)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.279
Part 2. Section I. Funding Opportunity Description
Institute Interests
NIDA
NIDA seeks to support research that investigates how drug use may impede the optimal engagement of men into HIV testing, prevention and care. NIDA's interests include the full range of licit and illicit drugs of use and abuse and all modes of drug administration (e.g., oral, smoking, nasal, injection). Populations of interest include those characterized only by drug use as well as key populations (e.g., gay men and other MSM) where drug use is common and a known contributor to risk for HIV acquisition or poor HIV outcomes.
Part 2. Section VII. Agency Contacts
Scientific/Research Contact(s)
Richard A. Jenkins, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: [email protected]
Financial/Grants Management Contact(s)
Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: [email protected]
All other aspects of the FOA remain the same.
Richard A. Jenkins, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: [email protected]